XAIR KOKICARE INC

Beyond Airâ„¢ Announces New NASDAQ Ticker Symbol is XAIR

Beyond Air™ Announces New NASDAQ Ticker Symbol is XAIR

New Ticker, XAIR, to be effective Monday, July 15, 2019

GARDEN CITY, N.Y. and REHOVOT, Israel, July 15, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it has changed its NASDAQ ticker symbol from AITB to XAIR.  The change is effective today, Monday, July 15, 2019.

Additional information can be found on the company’s website at .

About Beyond Air, Inc.

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The Beyond Air NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose.  The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit .

CONTACT

Steven Lisi, Chief Executive Officer

Beyond Air, Inc.



Bob Yedid

LifeSci Advisors, LLC

(646) 597-6989

 

EN
15/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KOKICARE INC

 PRESS RELEASE

Beyond Air™ to Participate at Two Upcoming Conferences

Beyond Air™ to Participate at Two Upcoming Conferences GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate at the two upcoming conferences.  Details are as follows: Conference details:  Oppenheimer Fall Summit Date:September 23, 2019Location:Parker New Y...

 PRESS RELEASE

Beyond Airâ„¢ to Present at the 21st Annual H.C. Wainwright Global Inv...

Beyond Air™ to Present at the 21st Annual H.C. Wainwright Global Investment Conference GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the 21st Annual H.C. Wainwright Global Investment Conference being held on September 8-10, 2019 at the Lotte New...

 PRESS RELEASE

Beyond Airâ„¢ Reports Financial Results for Fiscal First Quarter 2020

Beyond Air™ Reports Financial Results for Fiscal First Quarter 2020 Began trading under new ticker symbol, XAIR, on the NASDAQ stock exchange on July 15, 2019 Anticipate submitting a PMA for LungFit™* for the treatment of persistent pulmonary hypertension of the newborn (PPHN) in the third quarter of calendar 2019 Anticipate receiving CE Mark for LungFit™* in the first half of calendar 2020 for PPHN and pulmonary hypertension associated with cardiac surgery Conference Call scheduled for today, Wednesday, August 14th at 4:30 pm Eastern Time GARDEN CITY, N.Y. and REHOVOT, Israel, Aug. 14...

 PRESS RELEASE

Beyond Airâ„¢ Participating at the BTIG Biotechnology Conference on Au...

Beyond Air™ Participating at the BTIG Biotechnology Conference on August 12 GARDEN CITY, N.Y. and REHOVOT, Israel, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the BTIG Biotechnology Conference being held at the St. Regis Hotel in New York, NY on August 12, 2019. About Beyond Air, I...

 PRESS RELEASE

Beyond Airâ„¢ Schedules First Fiscal Quarter 2020 Financial Results Co...

Beyond Air™ Schedules First Fiscal Quarter 2020 Financial Results Conference Call and Webcast Call scheduled for Wednesday, August 14th at 4:30pm Eastern Time GARDEN CITY, N.Y. and REHOVOT, Israel, July 30, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced it will report financial results for its first fiscal quarter ended June 30, 2019 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch